Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

Koca D., Salman T., ÜNEK İ. T., ÖZTOP İ., ELLİDOKUZ H., Eren M., ...Daha Fazla

CHEMOTHERAPY, cilt.57, sa.5, ss.381-387, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 5
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1159/000331645
  • Dergi Adı: CHEMOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.381-387
  • Anahtar Kelimeler: Capecitabine, Heart, Side effects, BREAST-CANCER, CARDIOTOXICITY, 5-FLUOROURACIL, CHEMOTHERAPY, ANGINA, HEART
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: We aimed to identify the incidence of cardiac events with capecitabine treatment. Methods: The study included 52 patients (median age 59 years) with cancer treated at our Medical Oncology Clinic between 2009 and 2010. Cardiac events from capecitabine treatment were classified into 4 groups: cardiac symptoms, physical signs, electrocardiography (ECG) findings, and severe adverse cardiac effects. Results: The patients received either single-agent capecitabine or a combination chemotherapy including capecitabine. After initiation of capecitabine, 18 patients (34.6%) had new onset cardiovascular symptoms, 6 (11.5%) had new onset physical signs and 17 (32.6%) had new onset ECG findings. New onset ECG findings included prolonged corrected QT interval (n = 10, 19.2%) and prolonged PR interval (n = 3, 5.8%). Severe adverse capecitabine-induced cardiac side effects were observed in 5.8% of the patients, but none of the patients had myocardial infarction or died. Conclusion: Cardiac events are not rare during capecitebine treatment and patients should be followed closely to avoid cardiac morbidity and mortality. Copyright (C) 2011 S. Karger AG, Basel